Phenylpropanolamine Explained

Watchedfields:verified
Verifiedrevid:464201364
Iupac Name:(1R,2S)-2-amino-1-phenylpropan-1-ol
Alt2:Ball-and-stick model of the phenylpropanolamine molecule
Tradename:Many
Pregnancy Au:B2
Legal Au:S4
Legal Br:F3
Legal Br Comment:[1]
Legal Ca:Schedule VI
Legal Us Comment:Rx-Only
Routes Of Administration:By mouth
Bioavailability:High
Protein Bound:20%
Metabolism:Minimal (3–4%)
Metabolites:Hippuric acid (~4%)
4-Hydroxynorephedrine (≤1%)
Onset:Oral

15–30minutes

Elimination Half-Life:4 (3.7–4.9)hours[2]
Duration Of Action:Oral: 3hours
Excretion:Urine

90% (unchanged)

Cas Number:14838-15-4
Atc Prefix:R01
Atc Suffix:BA01
Pubchem:10297
Drugbank:DB00397
Chemspiderid:9875
Unii:33RU150WUN
Kegg:D08368
Chembl:136560
Synonyms:PPA; Norephedrine; α-Methyl-β-hydroxyphenethylamine; β-Hydroxyamphetamine
C:9
H:13
N:1
O:1
Smiles:O[C@H](c1ccccc1)[C@@H](N)C
Stdinchi:1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m0/s1
Stdinchikey:DLNKOYKMWOXYQA-CBAPKCEASA-N

Phenylpropanolamine (PPA), sold under many brand names, is a sympathomimetic agent which is used as a decongestant and appetite suppressant.[3] It was previously commonly used in prescription and over-the-counter cough and cold preparations. The medication is taken by mouth.

Side effects of PPA include increased heart rate and blood pressure, among others. Rarely, PPA has been associated with hemorrhagic stroke. PPA acts as a norepinephrine releasing agent, thereby indirectly activating adrenergic receptors.[4] [5] [6] As such, it is an indirectly acting sympathomimetic. It was previously thought to act as a mixed acting sympathomimetic with additional direct agonist actions on adrenergic receptors, but this proved not to be the case. Chemically, PPA is a substituted amphetamine and is closely related to ephedrine, pseudoephedrine, amphetamine, and cathinone.[7]

PPA was first synthesized around 1910 and its effects on blood pressure were first characterized around 1930. It was introduced for medical use by the 1930s. The medication was withdrawn from many markets starting in 2000 following findings that it was associated with increased risk of hemorrhagic stroke.[8] It was previously available both over-the-counter and by prescription. PPA remains available for medical and/or veterinary use in some countries.

Medical uses

PPA is used as a decongestant to treat nasal congestion.[9] [10] It has also been used to suppress appetite and promote weight loss in the treatment of obesity and has shown effectiveness for this indication.[11] [12] [13]

Available forms

PPA was previously available over-the-counter and in certain combination forms by prescription in the United States.[14] [15] However, these forms have all been discontinued. PPA remains available in certain other countries.

Side effects

PPA produces sympathomimetic effects and can cause side effects such as increased heart rate and blood pressure.[16] [17] It has been associated rarely with incidence of hemorrhagic stroke.

Certain drugs increase the chances of déjà vu occurring in the user, resulting in a strong sensation that an event or experience currently being experienced has already been experienced in the past. Some pharmaceutical drugs, when taken together, have also been implicated in the cause of déjà vu.[18] reported the case of an otherwise healthy male who started experiencing intense and recurrent sensations of déjà vu upon taking the drugs amantadine and PPA together to relieve flu symptoms. He found the experience so interesting that he completed the full course of his treatment and reported it to the psychologists to write up as a case study. Because of the dopaminergic action of the drugs and previous findings from electrode stimulation of the brain,[19] it was speculated that déjà vu occurs as a result of hyperdopaminergic action in the mesial temporal areas of the brain.

Interactions

There has been very little research on drug interactions with PPA. In one study, PPA taken with caffeine was found to quadruple caffeine levels. In another study, PPA reduced theophylline clearance by 50%.

Pharmacology

Pharmacodynamics

PPA acts primarily as a selective norepinephrine releasing agent. It also acts as a dopamine releasing agent with around 10-fold lower potency. The stereoisomers of the drug have only weak or negligible affinity for α- and β-adrenergic receptors.

Monoamine release by PPA and related agents (nM)[20]
Compound data-sort-type="number" !data-sort-type="number" !data-sort-type="number" !Ref
Dextroamphetamine (S(+)-amphetamine) 6.6–7.2 5.8–24.8 698–1765 [21] [22]
12.4 18.5 2366
43.1–72.4 236–1350 >10000
218 2104 >10000
Dextromethamphetamine (S(+)-methamphetamine) 12.3–13.8 8.5–24.5 736–1291.7 [23]
Levomethamphetamine (R(–)-methamphetamine) 28.5 416 4640
(+)-Phenylpropanolamine ((+)-norephedrine) 42.1 302 >10000
(–)-Phenylpropanolamine ((–)-norephedrine) 137 1371 >10000
Cathine ((+)-norpseudoephedrine) 15.0 68.3 >10000
30.1 294 >10000
4092 9125 >10000
Pseudoephedrine ((+)-pseudoephedrine) 224 1988 >10000
The smaller the value, the more strongly the substance releases the neurotransmitter. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds.

PPA was originally thought to act as a direct agonist of adrenergic receptors and hence to act as a mixed acting sympathomimetic, However, PPA was subsequently found to show only weak or negligible affinity for these receptors and has been instead characterized as exclusively an indirectly acting sympathomimetic. It acts by inducing norepinephrine release and thereby indirectly activating adrenergic receptors.

Many sympathetic hormones and neurotransmitters are based on the phenethylamine skeleton, and function generally in "fight or flight" type responses, such as increasing heart rate, blood pressure, dilating the pupils, increased energy, drying of mucous membranes, increased sweating, and a significant number of additional effects.

PPA has relatively low potency as a sympathomimetic. It is about 100 to 200times less potent than epinephrine (adrenaline) or norepinephrine (noradrenaline) in its sympathomimetic effects, although responses are variable depending on tissue.

Pharmacokinetics

Absorption

PPA is readily- and well-absorbed with oral administration.[24] Immediate-release forms of the drug reached peak levels about 1.5hours (range 1.0 to 2.3hours) following administration.[25] Conversely, extended-release forms of PPA reach peak levels after 3.0 to 4.5hours. The pharmacokinetics of PPA are linear across an oral dose range of 25 to 100mg. Steady-state levels of PPA are achieved within 12hours when the drug is taken once every 4hours. There is 62% accumulation of PPA at steady state in terms of peak levels, whereas area-under-the-curve levels are not increased with steady state.

Distribution

The volume of distribution of PPA is 3.0 to 4.5L/kg. Levels of PPA in the brain are about 40% of those in the heart and 20% of those in the lungs. The hydroxyl group of PPA at the β carbon increases its hydrophilicity, reduces its permeation through the blood–brain barrier, and limits its central nervous system (CNS) effects. Hence, PPA crosses into the brain only to some extent, has only weak CNS effects, and most of its effects are peripheral. In any case, PPA can produce amphetamine-like psychostimulant effects at very high doses. PPA is more lipophilic than structurally related sympathomimetics with hydroxyl groups on the phenyl ring like epinephrine (adrenaline) and phenylephrine and has greater brain permeability than these agents.

The plasma protein binding of PPA is approximately 20%. However, it has been said that no recent studies have substantiated this value.

Metabolism

PPA is not substantially metabolized. It also does not undergo significant first-pass metabolism. Only about 3 to 4% of an oral dose of PPA is metabolized. Metabolites include hippuric acid (via oxidative deamination of the side chain) and 4-hydroxynorephedrine (via para-hydroxylation). The methyl group at the α carbon of PPA blocks metabolism by monoamine oxidases (MAOs).[26] PPA is also not a substrate of catechol O-methyltransferase. The hydroxyl group at the β carbon of PPA also helps to increase metabolic stability.

Elimination

Approximately 90% of a dose of PPA is excreted in the urine unchanged within 24hours. About 4% of excreted material is in the form of metabolites.

The elimination half-life of immediate-release PPA is about 4hours, with a range in different studies of 3.7 to 4.9hours.[27] The half-life of extended-release PPA has ranged from 4.3 to 5.8hours.

The elimination of PPA is dependent on urinary pH. At a more acidic urinary pH, the elimination of PPA is accelerated and its half-life and duration are shortened, whereas at more basic urinary pH, the elimination of PPA is reduced and its half-life and duration are extended. Urinary acidifying agents like ascorbic acid and ammonium chloride can increase the excretion of and thereby reduce exposure to amphetamines including PPA, whereas urinary alkalinizing agents including antacids like sodium bicarbonate as well as acetazolamide can reduce the excretion of these agents and thereby increase exposure to them.[28] [29]

Total body clearance of PPA has been reported to be 0.546L/h/kg, while renal clearance was 0.432L/h/kg.

Miscellaneous

As PPA is not extensively metabolized, it would probably not be affected by hepatic impairment. Conversely, there is likely to be accumulation of PPA with renal impairment due to its dependence on urinary excretion.

Norephedrine is a minor metabolite of amphetamine and methamphetamine, as shown below. It is also a minor metabolite of ephedrine and a major metabolite of cathinone.

Chemistry

PPA, also known as α-methyl-β-hydroxyphenethylamine or as β-hydroxyamphetamine, is a substituted phenethylamine and amphetamine derivative.[30] [31] It is closely related to the cathinones (β-ketoamphetamines). The compound exists as four stereoisomers, which include d- (dextrorotatory) and l-norephedrine (levorotatory), and d- and l-norpseudoephedrine. d-Norpseudoephedrine is also known as cathine, and is found naturally in Catha edulis (khat).[32] Pharmaceutical drug preparations of PPA have varied in their stereoisomer composition in different countries, which may explain differences in misuse and side effect profiles. In any case, racemic dl-norephedrine appears to be the most commonly used formulation pharmaceutically. Analogues of PPA include ephedrine, pseudoephedrine, amphetamine, methamphetamine, and cathinone.

PPA, structurally, is in the substituted phenethylamine class, consisting of a cyclic benzene or phenyl group, a two carbon ethyl moiety, and a terminal nitrogen, hence the name phen-ethyl-amine. The methyl group on the alpha carbon (the first carbon before the nitrogen group) also makes this compound a member of the substituted amphetamine class. Ephedrine is the N-methyl analogue of PPA.

Exogenous compounds in this family are degraded too rapidly by monoamine oxidase to be active at all but the highest doses. However, the addition of the α-methyl group allows the compound to avoid metabolism and confer an effect. In general, N-methylation of primary amines increases their potency, whereas β-hydroxylation decreases CNS activity, but conveys more selectivity for adrenergic receptors.[33]

PPA is a small-molecule compound with the molecular formula C9H13NO and a molecular weight of 151.21g/mol.[34] [35] It has an experimental log P of 0.67, while its predicted log P values range from 0.57 to 0.89. The compound is relatively lipophilic,[36] but is also more hydrophilic than other amphetamines. The lipophilicity of amphetamines is closely related to their brain permeability.[37] For comparison to PPA, the experimental log P of methamphetamine is 2.1,[38] of amphetamine is 1.8,[39] of ephedrine is 1.1,[40] of pseudoephedrine is 0.7,[41] of phenylephrine is -0.3,[42] and of norepinephrine is -1.2.[43] Methamphetamine has high brain permeability, whereas phenylephrine and norepinephrine are peripherally selective drugs.[44] [45] The optimal log P for brain permeation and central activity is about 2.1 (range 1.5–2.7).[46]

PPA has been used pharmaceutically exclusively as the hydrochloride salt.

History

PPA was first synthesized in the early 20th century, in or around 1910.[47] It was patented as a mydriatic in 1913. The pressor effects of PPA were characterized in the late 1920s and the 1930s. PPA was first introduced for medical use by the 1930s.

In the United States, PPA is no longer sold due to an increased risk of haemorrhagic stroke.[48] In a few countries in Europe, however, it is still available either by prescription or sometimes over-the-counter. In Canada, it was withdrawn from the market on 31 May 2001.[49] It was voluntarily withdrawn from the Australian market by July 2001.[50] In India, human use of PPA and its formulations was banned on 10 February 2011,[51] but the ban was overturned by the judiciary in September 2011.[52]

Society and culture

Names

Phenylpropanolamine is the generic name of the drug and its,, and, while phenylpropanolamine hydrochloride is its and in the case of the hydrochloride salt.[53] [54] [55] It is also known by the synonym norephedrine.

Brand names of PPA have included Acutrim, Appedrine, Capton Diet, Control, Dexatrim, Emagrin Plus A.P., Glifentol, Kontexin, Merex, Monydrin, Mydriatine, Prolamine, Propadrine, Propagest, Recatol, Rinexin, Tinaroc, and Westrim, among many others.[56] It has also been used in combinations under brand names including Allerest, Demazin, Dimetapp, and Sinarest, among others.

Availability

PPA remains available for medical and veterinary use in certain countries.

Exercise and sports

There has been interest in PPA as a performance-enhancing drug in exercise and sports.[57] However, clinical studies suggest that PPA is not effective in this regard.[58] PPA is not on the World Anti-Doping Agency (WADA) list of prohibited substances as of 2024.[59]

Legal status

In Sweden, PPA is still available in prescription decongestants;[60] PPA is also still available in Germany. It is used in some polypill medications like Wick DayMed capsules.

In the United Kingdom, PPA was available in many "all in one" cough and cold medications which usually also feature paracetamol or another analgesic and caffeine and could also be purchased on its own; however, it is no longer approved for human use. A European Category 1 Licence is required to purchase PPA for academic use.

In the United States, the Food and Drug Administration (FDA) issued a public health advisory[61] against the use of the drug in November 2000. In this advisory, the FDA requested but did not require that all drug companies discontinue marketing products containing PPA. The agency estimates that PPA caused between 200 and 500 strokes per year among 18-to-49-year-old users. In 2005, the FDA removed PPA from over-the-counter sale and removed its "generally recognized as safe and effective" (GRASE) status.[62] Under the 2020 CARES Act, it requires FDA approval before it can be marketed again effectively banning the drug even as a prescription drug.[63]

Because of its potential use in amphetamine manufacture, PPA is controlled by the Combat Methamphetamine Epidemic Act of 2005. It is still available for veterinary use in dogs, however, as a treatment for urinary incontinence.

Internationally, an item on the agenda of the 2000 Commission on Narcotic Drugs session called for including the stereoisomer norephedrine in Table I of United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.[64]

Drugs containing PPA were banned in India on 27 January 2011.[65] On 13 September 2011, Madras High Court revoked a ban on manufacture and sale of pediatric drugs PPA and nimesulide.[66]

Veterinary use

PPA remains available for use in veterinary medicine. It is used to control urinary incontinence in dogs.[67] [68]

Notes and References

  1. Web site: Anvisa . Brazilian Health Regulatory Agency . 2023-07-24 . RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 . 2023-08-27 . 2023-08-27 . . pt-BR . 2023-07-25.
  2. Web site: Phenylpropanolamine: Uses, Interactions, Mechanism of Action . DrugBank Online . 29 June 2018 . 1 August 2024.
  3. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ . Safety of drug therapies used for weight loss and treatment of obesity . Drug Saf . 29 . 4 . 277–302 . 2006 . 16569079 . 10.2165/00002018-200629040-00001 .
  4. Rothman RB, Baumann MH . Therapeutic potential of monoamine transporter substrates . Curr Top Med Chem . 6 . 17 . 1845–1859 . 2006 . 17017961 . 10.2174/156802606778249766 .
  5. Rothman RB, Baumann MH . Targeted screening for biogenic amine transporters: potential applications for natural products . Life Sci . 78 . 5 . 512–518 . December 2005 . 16202429 . 10.1016/j.lfs.2005.09.001 .
  6. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA . In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates . J Pharmacol Exp Ther . 307 . 1 . 138–145 . October 2003 . 12954796 . 10.1124/jpet.103.053975 .
  7. Bravo EL . Phenylpropanolamine and other over-the-counter vasoactive compounds . Hypertension . 11 . 3 Pt 2 . II7–10 . March 1988 . 3280497 . 10.1161/01.hyp.11.3_pt_2.ii7 .
  8. Mersfelder TL . Phenylpropanolamine and stroke: the study, the FDA ruling, the implications . Cleve Clin J Med . 68 . 3 . 208–9, 213–9, 223 . March 2001 . 11263849 . 10.3949/ccjm.68.3.208 .
  9. Johnson DA, Hricik JG . The pharmacology of alpha-adrenergic decongestants . Pharmacotherapy . 13 . 6 Pt 2 . 110S–115S; discussion 143S–146S . 1993 . 7507588 .
  10. O'Donnell SR . Sympathomimetic vasoconstrictors as nasal decongestants . Med J Aust . 162 . 5 . 264–267 . March 1995 . 7534374 . 10.5694/j.1326-5377.1995.tb139882.x .
  11. Coulter AA, Rebello CJ, Greenway FL . Centrally Acting Agents for Obesity: Past, Present, and Future . Drugs . 78 . 11 . 1113–1132 . July 2018 . 30014268 . 6095132 . 10.1007/s40265-018-0946-y .
  12. Ioannides-Demos LL, Proietto J, McNeil JJ . Pharmacotherapy for obesity . Drugs . 65 . 10 . 1391–418 . 2005 . 15977970 . 10.2165/00003495-200565100-00006 .
  13. Greenway F, Herber D, Raum W, Herber D, Morales S . Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity . Obes Res . 7 . 4 . 370–378 . July 1999 . 10440593 . 10.1002/j.1550-8528.1999.tb00420.x .
  14. Web site: Drugs@FDA: FDA-Approved Drugs . Food and Drug Administration . accessdata.fda.gov . 1 August 2024.
  15. Web site: Search Results for phenylpropanolamine . DailyMed . 1 August 2024.
  16. Aaron CK . Sympathomimetics . Emerg Med Clin North Am . 8 . 3 . 513–526 . August 1990 . 2201518 .
  17. Salerno SM, Jackson JL, Berbano EP . The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature . J Hum Hypertens . 19 . 8 . 643–652 . August 2005 . 15944721 . 10.1038/sj.jhh.1001869 .
  18. Taiminen T, Jääskeläinen SK . Intense and recurrent déjà vu experiences related to amantadine and phenylpropanolamine in a healthy male . Journal of Clinical Neuroscience . 8 . 5 . 460–462 . September 2001 . 11535020 . 10.1054/jocn.2000.0810 . 6733989 .
  19. Bancaud J, Brunet-Bourgin F, Chauvel P, Halgren E . Anatomical origin of déjà vu and vivid 'memories' in human temporal lobe epilepsy . Brain . 117 . Pt 1 . 71–90 . February 1994 . 8149215 . 10.1093/brain/117.1.71 .
  20. Rothman RB, Baumann MH . Monoamine transporters and psychostimulant drugs . Eur. J. Pharmacol. . 479 . 1–3 . 23–40 . 2003 . 14612135 . 10.1016/j.ejphar.2003.08.054.
  21. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS . Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin . Synapse . 39 . 1 . 32–41 . January 2001 . 11071707 . 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 .
  22. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW . Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products . Neuropsychopharmacology . 38 . 4 . 552–562 . 2013 . 23072836 . 3572453 . 10.1038/npp.2012.204 .
  23. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV . The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue . Neuropsychopharmacology . 37 . 5 . 1192–203 . April 2012 . 22169943 . 3306880 . 10.1038/npp.2011.304 .
  24. Chua SS, Benrimoj SI, Triggs EJ . Pharmacokinetics of non-prescription sympathomimetic agents . Biopharm Drug Dispos . 10 . 1 . 1–14 . 1989 . 2647163 . 10.1002/bdd.2510100102 .
  25. Gentile DA, Friday GA, Skoner DP . Management of allergic rhinitis: antihistamines and decongestants . Immunology and Allergy Clinics of North America . 20 . 2 . 2000 . 10.1016/S0889-8561(05)70152-1 . 355–368.
  26. O'Donnell SR . Sympathomimetic vasoconstrictors as nasal decongestants . Med J Aust . 162 . 5 . 264–267 . March 1995 . 7534374 . 10.5694/j.1326-5377.1995.tb139882.x .
  27. Kanfer I, Dowse R, Vuma V . Pharmacokinetics of oral decongestants . Pharmacotherapy . 13 . 6 Pt 2 . 116S–128S; discussion 143S–146S . 1993 . 7507589 .
  28. Głowacka K, Wiela-Hojeńska A . Pseudoephedrine—Benefits and Risks . Int J Mol Sci . 22 . 10 . 5146 . May 2021 . 34067981 . 8152226 . 10.3390/ijms22105146 . free .
  29. Patrick KS, Markowitz JS . Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder . Human Psychopharmacology: Clinical and Experimental . 12 . 6 . 1997 . 0885-6222 . 10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO;2-U . 527–546.
  30. Book: Lemke TL, Williams DA . Foye's Principles of Medicinal Chemistry. 2008. Lippincott Williams & Wilkins. 978-0-7817-6879-5. 643–.
  31. Book: King LA . Forensic Chemistry of Substance Misuse: A Guide to Drug Control. 2009. Royal Society of Chemistry. 978-0-85404-178-7. 53–.
  32. Balint EE, Falkay G, Balint GA . Khat - a controversial plant . Wiener Klinische Wochenschrift . 121 . 19–20 . 604–614 . 2009 . 19921126 . 10.1007/s00508-009-1259-7 . 22816940 .
  33. Book: Brunton LL, Chabner BA, Knollmann BC . Goodman & Gilman's Pharmacological Basis of Therapeutics . 2010 . McGraw-Hill . New York . 9780071624428 . Westfall DP, Westfall TC . Chapter 12: Adrenergic Agonists and Antagonists: CLASSIFICATION OF SYMPATHOMIMETIC DRUGS . 12th . CHEMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIP OF SYMPATHOMIMETIC AMINES
    β-Phenylethylamine (Table 12–1) can be viewed as the parent compound of the sympathomimetic amines, consisting of a benzene ring and an ethylamine side chain. The structure permits substitutions to be made on the aromatic ring, the α- and β-carbon atoms, and the terminal amino group to yield a variety of compounds with sympathomimetic activity. ...N-methylation increases the potency of primary amines ...
    Substitution on the α-Carbon Atom
    This substitution blocks oxidation by MAO, greatly prolonging the duration of action of non-catecholamines because their degradation depends largely on the action of this enzyme. The duration of action of drugs such as ephedrine or amphetamine is thus measured in hours rather than in minutes. Similarly, compounds with an α-methyl substituent persist in the nerve terminals and are more likely to release NE from storage sites. Agents such as metaraminol exhibit a greater degree of indirect sympathomimetic activity.
    Substitution on the β-Carbon Atom
    Substitution of a hydroxyl group on the β carbon generally decreases actions within the CNS, largely because it lowers lipid solubility. However, such substitution greatly enhances agonist activity at both α- and β- adrenergic receptors. Although ephedrine is less potent than methamphetamine as a central stimulant, it is more powerful in dilating bronchioles and increasing blood pressure and heart rate..
  34. Web site: Phenylpropanolamine . PubChem . 1 August 2024.
  35. Web site: Phenylpropanolamine: Uses, Interactions, Mechanism of Action . DrugBank Online . 29 June 2018 . 1 August 2024.
  36. Chua SS, Benrimoj SI, Triggs EJ . Pharmacokinetics of non-prescription sympathomimetic agents . Biopharm Drug Dispos . 10 . 1 . 1–14 . 1989 . 2647163 . 10.1002/bdd.2510100102 .
  37. Bharate SS, Mignani S, Vishwakarma RA . Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis . J Med Chem . 61 . 23 . 10345–10374 . December 2018 . 29989814 . 10.1021/acs.jmedchem.7b01922 .
  38. Schep LJ, Slaughter RJ, Beasley DM . The clinical toxicology of metamfetamine . Clin Toxicol (Phila) . 48 . 7 . 675–694 . August 2010 . 20849327 . 10.3109/15563650.2010.516752 . Metamfetamine acts in a manner similar to amfetamine, but with the addition of the methyl group to the chemical structure. It is more lipophilic (Log p value 2.07, compared with 1.76 for amfetamine),4 thereby enabling rapid and extensive transport across the blood–brain barrier.19.
  39. Web site: Amphetamine . PubChem . 26 July 2024.
  40. Web site: Ephedrine . PubChem . 26 July 2024.
  41. Web site: Pseudoephedrine . PubChem . 1 August 2024.
  42. Web site: Phenylephrine . PubChem . 21 July 2024.
  43. Web site: Norepinephrine . PubChem . 26 July 2024.
  44. Eccles R . Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse . British Journal of Clinical Pharmacology . 63 . 1 . 10–14 . January 2007 . 17116124 . 2000711 . 10.1111/j.1365-2125.2006.02833.x .
  45. Froese L, Dian J, Gomez A, Unger B, Zeiler FA . The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature . Pharmacol Res Perspect . 8 . 5 . e00655 . October 2020 . 32965778 . 10.1002/prp2.655 . 7510331 .
  46. Pajouhesh H, Lenz GR . Medicinal chemical properties of successful central nervous system drugs . NeuroRx . 2 . 4 . 541–553 . October 2005 . 16489364 . 1201314 . 10.1602/neurorx.2.4.541 . Lipophilicity was the first of the descriptors to be identified as important for CNS penetration. Hansch and Leo54 reasoned that highly lipophilic molecules will partitioned into the lipid interior of membranes and will be retained there. However, ClogP correlates nicely with LogBBB with increasing lipophilicity increasing brain penetration. For several classes of CNS active substances, Hansch and Leo54 found that blood-brain barrier penetration is optimal when the LogP values are in the range of 1.5-2.7, with the mean value of 2.1. An analysis of small drug-like molecules suggested that for better brain permeation46 and for good intestinal permeability55 the LogD values need to be greater than 0 and less than 3. In comparison, the mean value for ClogP for the marketed CNS drugs is 2.5, which is in good agreement with the range found by Hansch et al.22.
  47. Johnson DA . Pharmacology and safety of phenylpropanolamine . Drug Development Research . 22 . 3 . 1991 . 0272-4391 . 10.1002/ddr.430220302 . 197–207.
  48. Yoon BW, Bae HJ, Hong KS, Lee SM, Park BJ, Yu KH, Han MK, Lee YS, Chung DK, Park JM, Jeong SW, Lee BC, Cho KH, Kim JS, Lee SH, Yoo KM . Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke . Neurology . 68 . 2 . 146–149 . January 2007 . 17210897 . 10.1212/01.wnl.0000250351.38999.f2 . 211233331 .
  49. Web site: Advisories, Warnings and Recalls – 2001 . https://web.archive.org/web/20100503164144/http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2001-eng.php . 3 May 2010 . 7 January 2009 . Health Canada.
  50. Web site: Alert Phenylpropanolamine . Therapeutic Goods Administration . 7 March 2006 . 31 December 2018.
  51. Web site: Drugs Banned In India . Central Drugs Standard Control Organization . Dte.GHS, Ministry of Health and Family Welfare, Government of India . 7 January 2014 . dead . https://web.archive.org/web/20131013222927/http://cdsco.nic.in/html/drugsbanned.html . 13 October 2013 . dmy-all .
  52. Web site: Madras High Court revokes ban on manufacture and sale of paediatric drugs nimesulide and PPA – India Medical Times.
  53. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer US . 2014 . 978-1-4757-2085-3 . 1 August 2024 . 71.
  54. Book: Schweizerischer Apotheker-Verein . Index Nominum 2000: International Drug Directory . Medpharm Scientific Publishers . Index nominum . 2000 . 978-3-88763-075-1 . 1 August 2024 . 828.
  55. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms . Springer Netherlands . 2012 . 978-94-011-4439-1 . 1 August 2024 . 219.
  56. Web site: Phenylpropanolamine . web.archive.org . 24 March 2015 . https://web.archive.org/web/20150506164657/http://www.drugs.com/international/phenylpropanolamine.html . 6 May 2015 . unfit . 1 August 2024.
  57. Jones G . Caffeine and other sympathomimetic stimulants: modes of action and effects on sports performance . Essays Biochem . 44 . 109–123 . 2008 . 18384286 . 10.1042/BSE0440109 .
  58. Bouchard R, Weber AR, Geiger JD . Informed decision-making on sympathomimetic use in sport and health . Clin J Sport Med . 12 . 4 . 209–224 . July 2002 . 12131054 . 10.1097/00042752-200207000-00003 .
  59. Web site: The Prohibited List . World Anti Doping Agency . 1 January 2024 . 1 August 2024.
  60. Web site: Rinexin in Farmaceutiska Specialiteter i Sverige . "Rinexin" from the Pharmaceutical Specialties of Sweden . drug catalog . sv . 7 January 2014.
  61. Phenylpopanolamine Advisory . https://web.archive.org/web/20100126085450/https://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052239.htm . 26 January 2010 . US Food and Drug Administration . 6 November 2000.
  62. Phenylpropanolamine (PPA) Information Page – FDA moves PPA from OTC . https://web.archive.org/web/20090112142816/https://www.fda.gov/cder/drug/infopage/ppa/ . 12 January 2009 . US Food and Drug Administration . 23 December 2005.
  63. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/over-counter-otc-drug-review-otc-monograph-reform-cares-act Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act
  64. Implementation of the international drug control treaties: changes in the scope of control of substances . https://web.archive.org/web/20030814040706/http://www.unodc.org/unodc/en/document_1999-12-21_1.html . 14 August 2003 . Commission on Narcotic Drugs, Forty-third session . Vienna . 6–15 March 2000.
  65. Web site: Unsafe Drugs- nimesulide, Cisapride, Phenylpropanolamine Banned. 27 January 2011.
  66. News: Madras High Court Revokes Ban on Manufacture and Sale PPA . Scribd.com . 13 September 2011 . 7 January 2014.
  67. Book: Gupta RC . Veterinary Toxicology: Basic and Clinical Principles. 23 April 2012. Academic Press. 978-0-12-385927-3. 458–.
  68. Book: Riviere JE, Papich MG . Veterinary Pharmacology and Therapeutics. 17 March 2009. John Wiley & Sons. 978-0-8138-2061-3. 1309–.